Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NovoCureBSP:N2VC34 48 Net-Net Working Capital is R$3.22 as of Jun. 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 48/100 and a GF Value™ of R$8.49 (Fairly Valued). The stock has 5 warning signs investors should review. Among 420 Medical Devices & Instruments companies, NovoCure ranks worse than 85% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
NovoCure's Net-Net Working Capital for the quarter that ended in Jun. 2026 was R$3.22.
The industry rank for NovoCure's Net-Net Working Capital or its related term are showing as below:
BSP:N2VC34's Price-to-Net-Net-Working-Capital is ranked worse than 85% of 420
companies
in the Medical Devices & Instruments industry
Industry Median: 6.71
vs BSP:N2VC34: 25.74
NovoCure (BSP:N2VC34) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
NovoCure Net-Net Working Capital Related Terms
NovoCure Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for NovoCure's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:N2VC34 vs NEOG, AXGN, UFPT: Net-Net Working Capital Comparison
For the Medical Devices subindustry, NovoCure's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where NovoCure's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of R$3.22 mean?
NovoCure (BSP:N2VC34) has a Net-Net Working Capital of R$3.22 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on NovoCure According to the industry distribution chart, NovoCure ranks #357 out of 420 companies in the Medical Devices & Instruments industry, placing it in the top 85%.
Is NovoCure's Net-Net Working Capital too high?
NovoCure's current Net-Net Working Capital is R$3.22. Based on the distribution chart, NovoCure ranks #357 out of 420 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NovoCure has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Net-Net Working Capital compare to NEOG and AXGN?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #357 out of 420 companies for Net-Net Working Capital. This places NovoCure in the lower half of its industry. The industry median Net-Net Working Capital is 6.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.71, based on 420 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on NovoCure For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current Net-Net Working Capital is R$3.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Fairly Valued. The stock's GF Value™ is R$8.49, compared to a current price of R$7.98 — trading 6% below its estimated fair value. The current Net-Net Working Capital is R$3.22. NovoCure's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current Net-Net Working Capital is R$3.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.98 is trading 6% below its estimated GF Value™ of R$8.49.
GuruFocus considers NovoCure to be Fairly Valued.
Key valuation signals for BSP:N2VC34:
Net-Net Working Capital: R$3.22
GF Value™: R$8.49 vs. price of R$7.98 (6% below fair value)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
48GF Score
Get the complete analysis for BSP:N2VC34
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
